Ionis Pharmaceuticals (IONS) — insider trading
Health Care · NASDAQ
Ionis Pharmaceuticals (IONS) has 28 reported SEC Form 4 insider transactions in our data, including 6 open-market sales among the most recent 28 (latest 2026-07-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | BERTHELSEN SPENCER R | Director | Option exercise / conversion (derivative) | 5,220 | $0.00 | $0 | Form 4 |
| 2026-07-15 | BERTHELSEN SPENCER R | Director | Option exercise / conversion | 5,220 | $0.00 | $0 | Form 4 |
| 2026-07-15 | HERMAN JOAN E | Director | Option exercise / conversion (derivative) | 5,220 | $0.00 | $0 | Form 4 |
| 2026-07-15 | HERMAN JOAN E | Director | Option exercise / conversion | 5,220 | $0.00 | $0 | Form 4 |
| 2026-07-15 | HANTSON LUDWIG | Director | Grant / award / vesting (derivative) | 3,399 | $0.00 | $0 | Form 4 |
| 2026-07-15 | Reikes Peter N | Director | Grant / award / vesting (derivative) | 3,399 | $0.00 | $0 | Form 4 |
| 2026-07-07 | Kordasiewicz Holly B. | Officer (EVP, Chief Development Officer) | Open-market sale | 362 | $84.30 | $30.5K | Form 4 |
| 2026-07-07 | Diaz Allene M. | Director | Option exercise / conversion (derivative) | 10,111 | $0.00 | $0 | Form 4 |
| 2026-07-07 | Diaz Allene M. | Director | Open-market sale | 10,111 | $85.42 | $863.6K | Form 4 |
| 2026-07-07 | Diaz Allene M. | Director | Option exercise / conversion | 10,111 | $47.11 | $476.3K | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Other acquisition or disposition (derivative) | 15,000 | $0.00 | $0 | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Open-market sale | 15,000 | $85.46 | $1.28M | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Other acquisition or disposition | 15,000 | $0.00 | $0 | Form 4 |
| 2026-07-07 | BENNETT C FRANK | Officer (EVP, Chief Scientific Officer) | Open-market sale | 5,536 | $83.58 | $462.7K | Form 4 |
| 2026-07-01 | Hayden Michael R | Director | Grant / award / vesting (derivative) | 2,301 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Hayden Michael R | Director | Grant / award / vesting (derivative) | 5,369 | $0.00 | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Grant / award / vesting (derivative) | 2,301 | $0.00 | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Grant / award / vesting (derivative) | 5,369 | $0.00 | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Option exercise / conversion (derivative) | 11,518 | $0.00 | $0 | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Open-market sale | 11,419 | $79.04 | $902.6K | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Open-market sale | 99 | $79.45 | $7.9K | Form 4 |
| 2026-07-01 | KLEIN JOSEPH III | Director | Option exercise / conversion | 11,518 | $39.94 | $460.0K | Form 4 |
| 2026-07-01 | HERMAN JOAN E | Director | Grant / award / vesting (derivative) | 2,301 | $0.00 | $0 | Form 4 |
| 2026-07-01 | HERMAN JOAN E | Director | Grant / award / vesting (derivative) | 5,369 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LOSCALZO JOSEPH | Director | Grant / award / vesting (derivative) | 2,301 | $0.00 | $0 | Form 4 |
| 2026-07-01 | LOSCALZO JOSEPH | Director | Grant / award / vesting (derivative) | 5,369 | $0.00 | $0 | Form 4 |
| 2026-07-01 | YANG MICHAEL J. | Director | Grant / award / vesting (derivative) | 2,301 | $0.00 | $0 | Form 4 |
| 2026-07-01 | YANG MICHAEL J. | Director | Grant / award / vesting (derivative) | 5,369 | $0.00 | $0 | Form 4 |
Ask the chat about IONS's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Ionis Pharmaceuticals (IONS).
Last updated 2026-07-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.